Company Overview

Skinvisible, Inc. (OTC: SKVI) is a U.S.-based pharmaceutical and dermatology-focused company that develops topical and transdermal drug delivery technologies. The company operates primarily in the healthcare and specialty pharmaceutical industries, with a focus on over-the-counter (OTC), prescription dermatological, and cosmetic applications. Its core business model centers on licensing and commercializing proprietary topical formulations and delivery systems designed to improve skin penetration, stability, and patient usability.

The company is best known for its proprietary Invisicare® technology platform, a polymer-based topical delivery system intended to enhance absorption and reduce residue on the skin. Skinvisible has historically pursued partnerships and licensing agreements with manufacturers and distributors rather than operating as a large-scale pharmaceutical manufacturer itself. The company evolved from a technology development enterprise into a commercialization-focused business targeting niche dermatology and personal care markets. Public filings and company disclosures indicate that Skinvisible has concentrated much of its effort on intellectual property development, licensing opportunities, and international commercialization relationships.

Business Operations

Skinvisible generates revenue primarily through product licensing arrangements, technology commercialization agreements, and limited direct product sales tied to its proprietary topical formulations. The company’s principal operating assets include its Invisicare® transdermal and topical delivery technology, related patents, and formulation expertise. The technology has been applied across multiple categories, including sunscreens, antimicrobial products, anti-inflammatory treatments, and cosmetic skin-care formulations.

Operations have historically included both domestic and international activities, particularly through distribution and commercialization agreements in foreign markets. Public disclosures reference relationships involving pharmaceutical and consumer health distributors in regions outside the United States, although the scale and continuity of these partnerships have varied over time. Skinvisible has also maintained involvement with antimicrobial and antiviral topical applications, including formulations marketed for healthcare and consumer use. Data regarding the current commercial scale of some partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Skinvisible’s strategic direction has centered on monetizing its intellectual property portfolio through licensing, co-development agreements, and commercialization partnerships. Rather than competing directly with large pharmaceutical manufacturers, the company has positioned itself as a specialty formulation and delivery-technology provider. This strategy is intended to reduce manufacturing overhead while leveraging external partners for distribution and market access.

The company has invested in expanding applications for Invisicare® across dermatological and healthcare categories, including antimicrobial and skincare products. Historical company disclosures and OTC market filings reference efforts to pursue opportunities in infection-control products and topical therapeutic formulations. Skinvisible has also explored international growth opportunities through regional licensing arrangements and product commercialization agreements. Publicly available information does not indicate major transformative acquisitions comparable to larger pharmaceutical companies, and some previously announced strategic initiatives appear to have remained in developmental or limited-commercialization stages.

Geographic Footprint

Skinvisible is headquartered in the United States, with corporate operations historically based in Nevada. The company’s business activities have primarily focused on North American markets, though its licensing and commercialization strategy has included outreach to international partners in regions such as Asia, Europe, and parts of Latin America.

The company’s international presence has generally been driven by distribution relationships and licensing arrangements rather than extensive owned manufacturing or operational infrastructure abroad. Public filings indicate that Skinvisible has sought international market penetration through third-party commercial partners, especially for skincare and antimicrobial products. However, publicly verifiable information regarding the current scale of ongoing international operations remains limited.

Leadership & Governance

Skinvisible was founded as a specialty topical technology company focused on commercializing proprietary dermatological delivery systems. Leadership over time has emphasized intellectual property development, licensing opportunities, and strategic commercialization partnerships within the healthcare and skincare sectors.

Key executives and leadership figures identified in public filings and corporate disclosures include:

• Terry Howlett – President and Chief Executive Officer
• Richard A. Brown – Former Chairman and Executive Officer associated with strategic corporate development
• Glenn Halperin – Financial executive roles referenced in historical company governance disclosures

The company’s governance approach has historically reflected the structure of a small public OTC-traded enterprise, with leadership focused on technology monetization, operational continuity, and partnership-driven growth strategies. Information regarding broader executive expansion, independent board activity, or large institutional governance structures is limited in publicly available disclosures.